Literature DB >> 8771577

Idiopathic fetal growth restriction: a pathophysiologic approach.

A Ghidini1.   

Abstract

Known causes of fetal growth restriction (FGR) can be traced in up to 40 percent of the cases. In the remainder of cases, FGR is idiopathic in origin. Evidence from experimental studies, antenatal findings at Doppler velocimetry of the uterine and umbilical arteries, and placental pathology studies suggests that idiopathic FGR can be divided into three groups: 1) primary abnormality in the uteroplacental perfusion; 2) primary abnormality in the fetoplacental perfusion; and 3) abnormal villous structure at the interface between fetal and maternal circulation. An improved understanding of the pathophysiology of idiopathic FGR is crucial to gain insight into its pathogenesis.

Mesh:

Year:  1996        PMID: 8771577     DOI: 10.1097/00006254-199606000-00023

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  21 in total

1.  Low birth weight followed by postnatal over-nutrition in the guinea pig exposes a predominant player in the development of vascular dysfunction.

Authors:  Jennifer A Thompson; Ousseynou Sarr; Karolina Piorkowska; Robert Gros; Timothy R H Regnault
Journal:  J Physiol       Date:  2014-10-31       Impact factor: 5.182

2.  Placental glucose transporter 3 (GLUT3) is up-regulated in human pregnancies complicated by late-onset intrauterine growth restriction.

Authors:  C Janzen; M Y Y Lei; J Cho; P Sullivan; B-C Shin; S U Devaskar
Journal:  Placenta       Date:  2013-08-28       Impact factor: 3.481

3.  Homeobox gene Distal-less 3 is a regulator of villous cytotrophoblast differentiation and its expression is increased in human idiopathic foetal growth restriction.

Authors:  Amy Chui; Charmaine Tay; Melanie Cocquebert; Penelope Sheehan; Niroshani A Pathirage; Susan Donath; Thierry Fournier; Josette Badet; Daniele Evain-Brion; Shaun P Brennecke; Bill Kalionis; Padma Murthi
Journal:  J Mol Med (Berl)       Date:  2011-11-24       Impact factor: 4.599

4.  Chorionic somatomammotropin impacts early fetal growth and placental gene expression.

Authors:  K M Jeckel; A C Boyarko; G J Bouma; Q A Winger; R V Anthony
Journal:  J Endocrinol       Date:  2018-04-16       Impact factor: 4.286

5.  Expression pattern of tumor necrosis factor alpha in placentae of idiopathic fetal growth restriction.

Authors:  Shaima M Almasry; Magda A Eldomiaty; Amr K Elfayomy; Fawzia A Habib
Journal:  J Mol Histol       Date:  2012-03-30       Impact factor: 2.611

6.  Chronic intrauterine hypoxia interferes with aortic development in the late gestation ovine fetus.

Authors:  Jennifer A Thompson; Bryan S Richardson; Robert Gagnon; Timothy R H Regnault
Journal:  J Physiol       Date:  2011-05-03       Impact factor: 5.182

7.  Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth.

Authors:  Sara Roos; Nina Jansson; Isabelle Palmberg; Karin Säljö; Theresa L Powell; Thomas Jansson
Journal:  J Physiol       Date:  2007-04-26       Impact factor: 5.182

8.  Uteroplacental adenovirus vascular endothelial growth factor gene therapy increases fetal growth velocity in growth-restricted sheep pregnancies.

Authors:  David J Carr; Jacqueline M Wallace; Raymond P Aitken; John S Milne; Vedanta Mehta; John F Martin; Ian C Zachary; Donald M Peebles; Anna L David
Journal:  Hum Gene Ther       Date:  2014-04-07       Impact factor: 5.695

9.  Development of ovine chorionic somatomammotropin hormone-deficient pregnancies.

Authors:  Callie M Baker; Lindsey N Goetzmann; Jeremy D Cantlon; Kimberly M Jeckel; Quinton A Winger; Russell V Anthony
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-02-17       Impact factor: 3.619

10.  Caffeine reduces 11β-hydroxysteroid dehydrogenase type 2 expression in human trophoblast cells through the adenosine A(2B) receptor.

Authors:  Saina Sharmin; Haiyan Guan; Andrew Scott Williams; Kaiping Yang
Journal:  PLoS One       Date:  2012-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.